StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) Benefit/Risk Profile Improves - Oppenheimer
March 19, 2019 9:39 AM
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $85.00 price target on Gilead Sciences (NASDAQ: GILD) after examining the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments